Market Place
Sourcing Support
RAPT Therapeutics Appoints Lori Lyons-Williams As Board Chair
06 Jan 2025 //
GLOBENEWSWIRE
Rapt pays $35M for challenger to Novartis, Roche drug
24 Dec 2024 //
FIERCE BIOTECH
RAPT Therapeutics Announces $150 Million Private Placement
23 Dec 2024 //
GLOBENEWSWIRE
RAPT Therapeutics Reports Q3 2024 Financial Results
12 Nov 2024 //
GLOBENEWSWIRE
Rapt`s share price sinks after shelving AD drug under FDA hold
11 Nov 2024 //
FIERCE BIOTECH
RAPT Therapeutics Stops Zelnecirnon Program After FDA Clinical Hold
11 Nov 2024 //
GLOBENEWSWIRE
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
08 Aug 2024 //
GLOBENEWSWIRE
RAPT Therapeutics Reports First Quarter 2024 Financial Results
09 May 2024 //
GLOBENEWSWIRE
Rallybio reigns in preclinical, Monopar pivots to radiopharma
09 May 2024 //
FIERCE BIOTECH
RAPT Therapeutics Reports Promising Tivumecirnon Results for Head& Neck Cancer
09 Apr 2024 //
GLOBENEWSWIRE
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
RAPT Therapeutics Announces Multiple Late-Breaking Presentations
05 Mar 2024 //
GLOBENEWSWIRE
FDA pauses RAPT’s immunology drug studies after patient experiences liver failure
21 Feb 2024 //
ENDPTS
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
20 Feb 2024 //
GLOBENEWSWIRE
RAPT Therapeutics Bolsters Leadership Team
13 Feb 2024 //
GLOBENEWSWIRE
RAPT Therapeutics’ stock plunges as FDA halts two clinical trials
01 Feb 2024 //
MARKETWATCH
RAPT to Participate in the Guggenheim Healthcare Talks 6th Annual Conference
31 Jan 2024 //
GLOBENEWSWIRE
RAPT Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
RAPT Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon
27 Nov 2023 //
GLOBENEWSWIRE
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
RAPT bolsters partner search with PhII data on small molecule-Keytruda combo
06 Nov 2023 //
ENDPTS
RAPT Therapeutics Announces Positive Data from its Phase 2 Trial of FLX475
03 Nov 2023 //
GLOBENEWSWIRE
RAPT Therapeutics to Participate in Several Investor Conferences in November
01 Nov 2023 //
GLOBENEWSWIRE
RAPT Therapeutics Announces Two FLX475 Presentations at SITC
18 Oct 2023 //
GLOBENEWSWIRE
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in Sep
30 Aug 2023 //
GLOBENEWSWIRE
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
11 Aug 2023 //
GLOBENEWSWIRE
RAPT Therapeutics to Participate in Goldman Sachs Global Healthcare Conference
07 Jun 2023 //
GLOBENEWSWIRE
RAPT to Present Data Demonstrated Clinical Activityof Action of FLX475
25 May 2023 //
GLOBENEWSWIRE
RAPT Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
RAPT Therapeutics Announces the Appointment of Michael Listgarten
03 May 2023 //
GLOBENEWSWIRE
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 ASCO
26 Apr 2023 //
GLOBENEWSWIRE
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193
29 Mar 2023 //
GLOBENEWSWIRE
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
14 Mar 2023 //
GLOBENEWSWIRE
RAPT to Participate in the SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Conference
03 Jan 2023 //
GLOBENEWSWIRE
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475
08 Dec 2022 //
GLOBENEWSWIRE
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the (ESMO)
30 Nov 2022 //
GLOBENEWSWIRE
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
17 Nov 2022 //
GLOBENEWSWIRE
Rapt Therapeutics Announces Proposed Public Offering Of Common Stock
17 Nov 2022 //
PRESS RELEASE
RAPT Therapeutics Reports Third Quarter 2022 Financial Results
10 Nov 2022 //
PRESS RELEASE
Rapt Therapeutics To Participate In Several Upcoming Investor Conferences
09 Nov 2022 //
PRESS RELEASE
RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires
28 Sep 2022 //
GLOBENEWSWIRE
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
GLOBENEWSWIRE
RAPT Therapeutics Announces Private Placement Financing of $50 Million
25 May 2022 //
GLOBENEWSWIRE
RAPT Therapeutics Initiates PIIb Trial of RPT193 in Atopic Dermatitis
23 May 2022 //
GLOBENEWSWIRE
RAPT Therapeutics Expands Leadership Team with Multiple Key Hires
04 May 2022 //
GLOBENEWSWIRE
RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193
28 Mar 2022 //
GLOBENEWSWIRE
RAPT Tx Reports Q4 and Year End 2021 Financial Results
10 Mar 2022 //
GLOBENEWSWIRE
RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Conference
09 Feb 2022 //
GLOBENEWSWIRE
RAPT Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
04 Jan 2022 //
GLOBENEWSWIRE
RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b
18 Oct 2021 //
GLOBENEWSWIRE
RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th EADVC
20 Sep 2021 //
GLOBENEWSWIRE
RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference
20 Sep 2021 //
GLOBENEWSWIRE
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
15 Jun 2021 //
GLOBENEWSWIRE
Rapt Therapeutics Shares Rally After Eczema Drug Candidate Shows Potential
14 Jun 2021 //
MARKET WATCH
RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193
14 Jun 2021 //
GLOBENEWSWIRE
RAPT Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dermatitis
22 Mar 2021 //
GLOBENEWSWIRE
RAPT Therapeutics to Report Promising Preclinical Studies Supporting
10 Mar 2021 //
GLOBENEWSWIRE
RAPT Reports Positive Initial Data from Phase 1/2 Trial of FLX475
16 Nov 2020 //
GLOBENEWSWIRE
RAPT Therapeutics Appoints Phyllis Loud Gray as VP of Human Resources
05 Aug 2020 //
GLOBENEWSWIRE
